Previous close | 331.00 |
Open | 331.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 331.00 - 331.00 |
52-week range | 3.96 - 353.50 |
Volume | |
Avg. volume | 3 |
Market cap | 21.663B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | 68.12 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Media Release COPENHAGEN, Denmark; June 05, 2024Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida 9:20 AM EDT (3:20 PM CEST) on June 10, 2024. A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is
Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 27, 2024 to May 31, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement
COPENHAGEN, Denmark, June 03, 2024--Genmab A/S (Nasdaq: GMAB) announced today that data from the Phase 2 innovaTV 207 trial (NCT03485209) Part C (n=40), investigating tisotumab vedotin, an antibody-drug conjugate directed to tissue factor, demonstrated encouraging antitumor activity as a monotherapy in patients with head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on or after first-line therapy. The study showed 32.5% of patients achieved a confirmed objective re